FDA approves Nexium for treatment of teens

Share this article:
The FDA this week cleared AstraZeneca to market its heartburn treatment Nexium to children ages 12 through 17 for the treatment of gastroesophageal reflux disease. Nexium had global sales of $4.6 billion in 2005, making it the fifth best-selling drug in the world. The drug was approved for use in adults in February 2001.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.